{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T10:49:43Z","timestamp":1785408583438,"version":"3.56.0"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2019,8,2]],"date-time":"2019-08-02T00:00:00Z","timestamp":1564704000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,8,2]],"date-time":"2019-08-02T00:00:00Z","timestamp":1564704000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin J Gastroenterol"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1007\/s12328-019-01029-y","type":"journal-article","created":{"date-parts":[[2019,8,2]],"date-time":"2019-08-02T14:02:54Z","timestamp":1564754574000},"page":"592-597","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Successful prolonged treatment of glecaprevir\/pibrentasvir for chronic hepatitis C patient with treatment failure after 8-week therapy: a case report"],"prefix":"10.1007","volume":"12","author":[{"given":"Atsushi","family":"Naganuma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3202-7983","authenticated-orcid":false,"given":"Ken","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toru","family":"Fukuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Namikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoru","family":"Kakizaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshio","family":"Uraoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Ohnishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Okamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,8,2]]},"reference":[{"key":"1029_CR1","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1007\/s00535-017-1391-5","volume":"53","author":"K Chayama","year":"2018","unstructured":"Chayama K, Suzuki F, Karino Y, et al. Efficacy and safety of glecaprevir\/pibrentasvir in Japanese patients with chronic genotype 1 hepatitis C virus infection with and without cirrhosis. J Gastroenterol. 2018;53:557\u201365.","journal-title":"J Gastroenterol."},{"key":"1029_CR2","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1002\/hep.29510","volume":"67","author":"H Toyoda","year":"2018","unstructured":"Toyoda H, Chayama K, Suzuki F, et al. Efficacy and safety of glecaprevir\/pibrentasvir in Japanese patients with chronic genotype 2 hepatitis C virus infection. Hepatology. 2018;67:505\u201313.","journal-title":"Hepatology."},{"key":"1029_CR3","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1007\/s00535-017-1396-0","volume":"53","author":"H Kumada","year":"2018","unstructured":"Kumada H, Watanabe T, Suzuki F, et al. Efficacy and safety of glecaprevir\/pibrentasvir in HCV-infected Japanese patients with prior DAA experience, severe renal impairment, or genotype 3 infection. J Gastroenterol. 2018;53:566\u201375.","journal-title":"J Gastroenterol."},{"key":"1029_CR4","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1007\/s12072-018-9878-6","volume":"12","author":"N Izumi","year":"2018","unstructured":"Izumi N, Takehara T, Chayama K, et al. Sofosbuvir-velpatasvir plus ribavirin in Japanese patients with genotype 1 or 2 hepatitis C who failed direct-acting antivirals. Hepatol Int. 2018;12:356\u201367.","journal-title":"Hepatol Int."},{"key":"1029_CR5","unstructured":"Interview form of Maviret\u00ae version 5; 2019. p 55. \nhttps:\/\/a-connect.abbvie.co.jp\/-\/media\/assets\/pdf\/products\/maviret\/if_Maviret_j.pdf\n\n. Accessed July 2019."},{"key":"1029_CR6","unstructured":"Interview form of Maviret\u00ae version 5; 2019. p 58. \nhttps:\/\/a-connect.abbvie.co.jp\/-\/media\/assets\/pdf\/products\/maviret\/if_Maviret_j.pdf\n\n. Accessed July 2019."},{"key":"1029_CR7","doi-asserted-by":"publisher","first-page":"4304","DOI":"10.3748\/wjg.v24.i38.4304","volume":"24","author":"K Sato","year":"2018","unstructured":"Sato K, Uraoka T. Challenge to overcome: nonstructural protein 5A-P32 deletion in direct-acting antiviral-based therapy for hepatitis C virus. World J Gastroenterol. 2018;24:4304\u201310.","journal-title":"World J Gastroenterol."},{"key":"1029_CR8","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1002\/jmv.24767","volume":"89","author":"N Akuta","year":"2017","unstructured":"Akuta N, Sezaki H, Suzuki F, et al. Ledipasvir plus sofosbuvir as salvage therapy for HCV genotype 1 failures to prior NS5A inhibitors regimens. J Med Virol. 2017;89:1248\u201354.","journal-title":"J Med Virol."},{"key":"1029_CR9","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1111\/hepr.13074","volume":"48","author":"H Ikeda","year":"2018","unstructured":"Ikeda H, Watanabe T, Shimizu H, et al. Efficacy of ledipasvir\/sofosbuvir with or without ribavirin for 12\u00a0weeks in genotype 1b HCV patients previously treated with a nonstructural protein 5A inhibitor-containing regimen. Hepatol Res. 2018;48:802\u20139.","journal-title":"Hepatol Res."},{"key":"1029_CR10","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1007\/s00535-017-1328-z","volume":"52","author":"G Suda","year":"2017","unstructured":"Suda G, Ogawa K, Yamamoto Y, et al. Retreatment with sofosbuvir, ledipasvir, and add-on ribavirin for patients who failed daclatasvir and asunaprevir combination therapy. J Gastroenterol. 2017;52:1122\u20139.","journal-title":"J Gastroenterol."},{"key":"1029_CR11","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1002\/jmv.25278","volume":"91","author":"N Akuta","year":"2019","unstructured":"Akuta N, Sezaki H, Suzuki F, et al. Favorable efficacy of glecaprevir plus pibrentasvir as salvage therapy for HCV failures to prior direct-acting antivirals regimens. J Med Virol. 2019;91:102\u20136.","journal-title":"J Med Virol."},{"key":"1029_CR12","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1007\/s00535-018-1520-9","volume":"54","author":"M Osawa","year":"2019","unstructured":"Osawa M, Imamura M, Teraoka Y, et al. Real-world efficacy of glecaprevir plus pibrentasvir for chronic hepatitis C patient with previous direct-acting antiviral therapy failures. J Gastroenterol. 2019;54:291\u20136.","journal-title":"J Gastroenterol."},{"key":"1029_CR13","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1111\/hepr.13328","volume":"49","author":"E Ogawa","year":"2019","unstructured":"Ogawa E, Furusyo N, Nakamuta M, et al. Glecaprevir and Pibrentasvir for Japanese patients with chronic hepatitis C genotype 1 or 2 infection: Results from a multicenter, real-world cohort study. Hepatol Res. 2019;49:617\u201326.","journal-title":"Hepatol Res."},{"key":"1029_CR14","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1016\/j.jhep.2019.01.031","volume":"70","author":"D Wyles","year":"2019","unstructured":"Wyles D, Weiland O, Yao B, et al. Retreatment of patients who failed glecaprevir\/pibrentasvir treatment for hepatitis C virus infection. J Hepatol. 2019;70:1019\u201323.","journal-title":"J Hepatol."},{"key":"1029_CR15","unstructured":"Interview form of Maviret\u00ae version 5; 2019. p 62. \nhttps:\/\/a-connect.abbvie.co.jp\/-\/media\/assets\/pdf\/products\/maviret\/if_Maviret_j.pdf\n\n. Accessed July 2019."},{"key":"1029_CR16","doi-asserted-by":"publisher","first-page":"525","DOI":"10.5604\/01.3001.0011.7398","volume":"17","author":"EJ Smolders","year":"2018","unstructured":"Smolders EJ, Willemse SB, El-Sherif O, et al. The observed effect of gastric bypass surgery on direct-acting antiviral treatment: a case report. Ann Hepatol. 2018;17:525\u20139.","journal-title":"Ann Hepatol."}],"container-title":["Clinical Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12328-019-01029-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12328-019-01029-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12328-019-01029-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T09:33:21Z","timestamp":1596274401000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12328-019-01029-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,2]]},"references-count":16,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1029"],"URL":"https:\/\/doi.org\/10.1007\/s12328-019-01029-y","relation":{},"ISSN":["1865-7257","1865-7265"],"issn-type":[{"value":"1865-7257","type":"print"},{"value":"1865-7265","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,2]]},"assertion":[{"value":"1 April 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 August 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Sato K received lecture fees from MSD K.K. and AbbVie Inc., and research funding from AbbVie. Kakizaki S received lecture fees from MSD K.K., AbbVie Inc. and Gilead Sciences, Inc., and research funding from BMS K.K. and Gilead Sciences, Inc.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures followed have been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human rights"}},{"value":"Informed consent was obtained from the patient for being included in the Case report.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}